Relief for long-suffering investors in Mela Sciences (MELA +4.1%) may soon be at hand, Barron's writes. The maker of a promising device for diagnosis cancer said last week that the FDA had finally issued an "approvals letter," which analysts say should help it resolve all remaining issues before a final vote.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs